Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003357 | 0.84 | KMT2A (0.58) | KMT2AMEN1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL25934739 | 0.83 | EGLN2 (0.65) | EGLN2FTOSMN1; SMN2HPGDLMNA | |
| SCHEMBL8779266 | 0.81 | EGLN2 (0.70) | EGLN2FTO | |
| SCHEMBL8135880 | 0.81 | EGLN2 (0.62) | EGLN2FTOHPGDLMNA | |
| SCHEMBL19808941 | 0.80 | EGLN1 (0.74) | FTOKMT2AMEN1L3MBTL1GLA | |
| SCHEMBL19808952 | 0.79 | TDP1 (0.59) | EGLN2FTOKMT2AL3MBTL1LMNA | |
| SCHEMBL31026221 | 0.79 | EGLN2 (0.68) | EGLN2FTOKMT2AGAA | |
| SCHEMBL704958 | 0.79 | FTO (1.00) | EGLN2FTO | |
| SCHEMBL8143835 | 0.78 | EGLN2 (0.58) | EGLN2FTOKMT2AMEN1HPGD | |
| SCHEMBL8144511 | 0.78 | EGLN2 (0.58) | EGLN2FTOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |